IntegraGen SA.
IntegraGen SA is at the stage of commercializing a series of innovative IntegraTests™ to position itself as a leader within the rapidly growing market of predictive medicine. By applying its proprietary gene-mapping technology GenomeHIP™ (Genome Hybrid Identity Profiling) in premier patient collections, IntegraGen has rapidly discovered novel genes and genetic markers associated with a variety of complex, multifactorial diseases to use in its IntegraTests - a new class of personalized medicine diagnostics. IntegraTests provide prediction, prevention, detailed diagnosis and tailored treatment of complex diseases. Depending on the disease and the applied set of genetic markers, these tests can calculate the personal risk for acquiring the disease, define the various subforms of complex diseases, predict susceptibility to severe comorbidities, and help to define a personalized health management program. Focusing on metabolic syndrome and neuropsychiatric disorders, IntegraGen will launch its first tests in Europe in 2005.